These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31569697)

  • 1. Development of
    Zhou Y; Banday AH; Hruby VJ; Cai M
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31569697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
    Lu BL; Williams GM; Verdon DJ; Dunbar PR; Brimble MA
    J Med Chem; 2020 Mar; 63(5):2282-2291. PubMed ID: 31418565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys.
    Zeng W; Eriksson E; Chua B; Grollo L; Jackson DC
    Amino Acids; 2010 Jul; 39(2):471-80. PubMed ID: 20091415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer.
    Kang JY; Nan X; Jin MS; Youn SJ; Ryu YH; Mah S; Han SH; Lee H; Paik SG; Lee JO
    Immunity; 2009 Dec; 31(6):873-84. PubMed ID: 19931471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
    Willems MM; Zom GG; Khan S; Meeuwenoord N; Melief CJ; van der Stelt M; Overkleeft HS; Codée JD; van der Marel GA; Ossendorp F; Filippov DV
    J Med Chem; 2014 Aug; 57(15):6873-8. PubMed ID: 25019313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.
    Pandey SP; Chandel HS; Srivastava S; Selvaraj S; Jha MK; Shukla D; Ebensen T; Guzman CA; Saha B
    J Immunol; 2014 Oct; 193(7):3632-43. PubMed ID: 25194056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Lipopeptides as Toll-like Receptor 2 Ligands.
    Hussein WM; Choi PM; Zhang C; Su M; Sierecki E; Johnston W; Fagan V; Alexandrov K; Skwarczynski M; Gambin Y; Toth I; Simerska P
    Curr Drug Deliv; 2017; 14(7):935-943. PubMed ID: 27494158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
    Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
    Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple synthetic toll-like receptor 2 ligands.
    Abdel-Aal AB; Al-Isae K; Zaman M; Toth I
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5863-5. PubMed ID: 21855334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 6-independent signaling by diacylated lipopeptides.
    Buwitt-Beckmann U; Heine H; Wiesmüller KH; Jung G; Brock R; Akira S; Ulmer AJ
    Eur J Immunol; 2005 Jan; 35(1):282-9. PubMed ID: 15580661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
    Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR2 agonists and their structure-activity relationships.
    Lu BL; Williams GM; Brimble MA
    Org Biomol Chem; 2020 Jul; 18(27):5073-5094. PubMed ID: 32582902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Toll-Like Receptor 2 agonist PEG-Pam
    Ernest M; Hunja C; Arakura Y; Haraga Y; Abkallo HM; Zeng W; Jackson DC; Chua B; Culleton R
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):451-458. PubMed ID: 30396012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.
    Akazawa T; Ohashi T; Wijewardana V; Sugiura K; Inoue N
    Cancer Sci; 2018 May; 109(5):1319-1329. PubMed ID: 29575556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
    Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
    Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.
    Moyle PM; Dai W; Zhang Y; Batzloff MR; Good MF; Toth I
    Bioconjug Chem; 2014 May; 25(5):965-78. PubMed ID: 24712905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists.
    Salyer ACD; David SA
    Hum Vaccin Immunother; 2018 Jul; 14(7):1686-1696. PubMed ID: 29852079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopeptides are signaled by Toll-like receptor 1, 2 and 6 in endolysosomes.
    Motoi Y; Shibata T; Takahashi K; Kanno A; Murakami Y; Li X; Kasahara T; Miyake K
    Int Immunol; 2014 Oct; 26(10):563-73. PubMed ID: 24860120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening.
    Guan Y; Omueti-Ayoade K; Mutha SK; Hergenrother PJ; Tapping RI
    J Biol Chem; 2010 Jul; 285(31):23755-62. PubMed ID: 20504771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.
    Chua BY; Zeng W; Jackson DC
    Methods Mol Biol; 2008; 494():247-61. PubMed ID: 18726578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.